Literature DB >> 30917930

MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells.

Mingqi Wang1, Renwen Zhang2, Shu Zhang3, Rui Xu4, Qing Yang5.   

Abstract

MicroRNA-574-3p (miR-574-3p) has different roles in different cancer types. However, the exact regulation mechanism of miR-574-3p in gastric cancer (GC) progression remains unclear. Thus, we aimed to evaluate the role of miR-574-3p in GC metastasis. We investigated the mechanism via which miR-574-3p regulated cancer cell migration and invasion to determine the relationship between epithelial mesenchymal transition (EMT) and drug resistance. Our results indicated that human GC cell line SGC7901 cells were more sensitive to cisplatin (DDP), but SGC7901 cisplatin-resistant cells (SGC7901/DDP) were more resistant to DDP and had mesenchymal characteristics. In addition, miR-574-3p overexpression up-regulated E-cadherin expression, and concomitantly down-regulated the expression of vimentin. We also identified zinc finger E-box binding homeobox transcription factor 1 (ZEB1), a crucial EMT inducer gene, as a new target of miR-574-3p. In fact, miR-574-3p bound the 3' untranslated region (3'-UTR) of ZEB1, regulating expression of this transcription factor at both the mRNA and protein levels. Furthermore, miR-574-3p overexpression reduced the migratory and invasive properties of the SGC7901/DDP cells and inhibited cisplatin (DDP) resistance in vitro and in vivo. In conclusion, the results indicated that miR-574-3p inhibited the EMT and enhanced cisplatin sensitivity in GC cells by suppressing ZEB1. These results provide further evidence for the critical roles of miR-574-3p and ZEB1 in invasion and migration regulation characteristics of GC cells.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cisplatin resistance; Epithelial mesenchymal transition; Gastric cancer; ZEB1; miR-574-3p

Mesh:

Substances:

Year:  2019        PMID: 30917930     DOI: 10.1016/j.gene.2019.03.043

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  21 in total

1.  Inhibition of ZEB1-AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation.

Authors:  Jin Gao; Yuan Yuan; Lili Zhang; Shaorong Yu; Jianwei Lu; Jifeng Feng; Sainan Hu
Journal:  Cancer Cell Int       Date:  2020-03-23       Impact factor: 5.722

2.  LINC00997/MicroRNA 574-3p/CUL2 Promotes Cervical Cancer Development via Mitogen-Activated Protein Kinase Signaling.

Authors:  Daming Chu; Tengteng Liu; Yuan Yao; Nannan Luan
Journal:  Mol Cell Biol       Date:  2021-07-23       Impact factor: 4.272

3.  MiRNA-574-3p inhibits cell progression by directly targeting CCND2 in colorectal cancer.

Authors:  Wen-Cui Li; Yan-Qiong Wu; Bo Gao; Chao-Yun Wang; Juan-Juan Zhang
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

4.  FOXK1, Regulated by miR-365-3p, Promotes Cell Growth and EMT Indicates Unfavorable Prognosis in Breast Cancer.

Authors:  Fucun Gao; Juan Tian
Journal:  Onco Targets Ther       Date:  2020-01-21       Impact factor: 4.147

Review 5.  Oncogenic functions of ZEB1 in pediatric solid cancers: interplays with microRNAs and long noncoding RNAs.

Authors:  Lívia Fratini; Mariane Jaeger; Caroline Brunetto de Farias; André T Brunetto; Algemir L Brunetto; Lisa Shaw; Rafael Roesler
Journal:  Mol Cell Biochem       Date:  2021-07-22       Impact factor: 3.396

Review 6.  Cancer drug resistance induced by EMT: novel therapeutic strategies.

Authors:  Javier De Las Rivas; Anamaria Brozovic; Sivan Izraely; Alba Casas-Pais; Isaac P Witz; Angélica Figueroa
Journal:  Arch Toxicol       Date:  2021-05-18       Impact factor: 5.153

7.  Inhibition of ZEB1-AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation.

Authors:  Jin Gao; Yuan Yuan; Lili Zhang; Shaorong Yu; Jianwei Lu; Jifeng Feng; Sainan Hu
Journal:  Cancer Cell Int       Date:  2020-03-23       Impact factor: 5.722

Review 8.  MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies.

Authors:  Hyun Ah Seo; Sokviseth Moeng; Seokmin Sim; Hyo Jeong Kuh; Soo Young Choi; Jong Kook Park
Journal:  Cells       Date:  2019-12-20       Impact factor: 6.600

Review 9.  Noncoding RNAs in gastric cancer: implications for drug resistance.

Authors:  Ling Wei; Jujie Sun; Nasha Zhang; Yan Zheng; Xingwu Wang; Liyan Lv; Jiandong Liu; Yeyang Xu; Yue Shen; Ming Yang
Journal:  Mol Cancer       Date:  2020-03-19       Impact factor: 27.401

10.  An Anti-inflammatory microRNA Signature Distinguishes Group 3 Innate Lymphoid Cells From Natural Killer Cells in Human Decidua.

Authors:  Andrea Pelosi; Claudia Alicata; Nicola Tumino; Tiziano Ingegnere; Fabrizio Loiacono; Maria Cristina Mingari; Lorenzo Moretta; Paola Vacca
Journal:  Front Immunol       Date:  2020-02-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.